The options paper suggested a capped special funding program separate from the PBS or a legislative change to enable conditional listings on the PBS. The special funding program would be more straightforward and timely. …
A simple, timely option for a 'bridging fund' that can fit within the existing legal framework
July 10, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech -
Starpharma raises $32 Million to advance dendrimer cancer programs
July 15, 2026 - - Australian Biotech -
Minister recommits to keeping MS medicines on the PBS while awaiting formal advice
July 15, 2026 - - Latest News -
Budget outlook now hangs on disability savings, but what about pharmaceuticals
July 15, 2026 - - Latest News -
Australian partnership advances gene therapy for Retinitis Pigmentosa
July 15, 2026 - - Latest News -
Patients move to reclaim access agenda ahead of sector negotiations
July 15, 2026 - - Latest News -
An opportunity to become a global destination for paediatric oncology trials
July 15, 2026 - - Latest News